Gastric Metastasis from Renal Cell Carcinoma, Clear Cell Type, Presenting with Gastrointestinal Bleeding

Mouhanna Abu Ghanimeh

Ayman Qasrawi

Omar Abughanimeh

Sakher Albadarin

John H. Helzberg

Follow this and additional works at: https://scholarlycommons.henryford.com/gastroenterology_articles

Recommended Citation
Case Rep Gastrointest Med 2017; 2017:5879374.

This Article is brought to you for free and open access by the Gastroenterology at Henry Ford Health System Scholarly Commons. It has been accepted for inclusion in Gastroenterology Articles by an authorized administrator of Henry Ford Health System Scholarly Commons.
Case Report

Gastric Metastasis from Renal Cell Carcinoma, Clear Cell Type, Presenting with Gastrointestinal Bleeding

Mouhanna Abu Ghanimeh,1 Ayman Qasrawi,2 Omar Abughanimeh,2 Sakher Albadarin,3 and John H. Helzberg4

1Internal Medicine Department, Division of Gastroenterology, Henry Ford Hospital, Detroit, MI, USA
2Internal Medicine Department, University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA
3Division of Gastroenterology, University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA
4Saint Luke's Hospital of Kansas City, University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA

Correspondence should be addressed to Mouhanna Abu Ghanimeh; mouhannaka87@yahoo.com

Received 17 May 2017; Revised 12 July 2017; Accepted 27 July 2017; Published 29 August 2017

Abstract

Renal cell carcinoma (RCC) accounts for 80–85% of all primary renal neoplasms. Although RCC can metastasize to any organ, gastric metastases from RCC are exceedingly rare. A 67-year-old male presented with melena and acute blood loss anemia. The patient had a history of RCC that had been treated with a radical nephrectomy. He had a recent myocardial infarction and was receiving double antiplatelet therapy. After hemodynamic stabilization, esophagogastroduodenoscopy showed a polypoid mass in the gastric fundus. The mass was excised. Histological and immunohistochemical evaluation were consistent with clear cell RCC. The polypoid lesion is consistent with a late solitary metastasis.

1. Introduction

Renal cell carcinoma (RCC) is the most common cancer originating from the kidney [1]. Lungs, bones, liver, and brain are the most common sites of RCC metastasis [2, 3]. Uncommon metastatic sites, including the gastrointestinal tract [2–4], have also been reported. Gastric metastasis from RCC is rare [5, 6]. Gastric metastases are typically asymptomatic, single, and located in the gastric body or fundus [5, 6]. If they are symptomatic, then gastrointestinal bleeding and anemia are the most common presentations [5, 6]. RCC has the potential for late solitary metastasis. Isolated gastric metastasis from RCC can occur up to 20 years after radical nephrectomy [7]. Immunohistochemistry is useful and increasingly utilized in the diagnosis of RCC [8, 9]. The prognosis in patients with metastatic RCC is generally poor, with a five-year survival rate of 5–30% [10]. Treatment options include embolization and epinephrine injection for bleeding and endoscopic resection or surgery [11–16]. Surgical resection remains the best therapeutic option for a solitary gastric metastasis, resulting in significant survival prolongation in eligible patients [8].

2. Case Summary

A 67-year-old man presented with multiple episodes of melena. His past medical history involved polycystic kidney disease, live donor renal transplantation in 2002 with chronic immunosuppression, and metastatic left-sided RCC that had been treated with radical nephrectomy and the resection of a pulmonary metastasis in 2014. The patient had chronic kidney disease, stage 3, and a recent ST segment elevation myocardial infarction with percutaneous coronary intervention and drug eluting stent insertion. The patient was on 81 mg of aspirin daily and 90 mg of ticagrelor twice daily.

His vital signs on presentation were blood pressure of 121/82 mmHg, pulse of 105 bpm, and oral temperature of 97.7° F (36.5 C). On physical examination, the patient was pale and in mild distress. Abdominal and cardiopulmonary exams
Figure 1: EGD showing a 2.5 to 3.0 cm polypoid mass in the gastric fundus.

were unremarkable. Initial laboratory evaluation included a hemoglobin (Hb) level of 8.8 g/dl (normal: 13.5–17.5 g/dl), white blood cell (WBC) count of 11,300/cmm (normal: 4,000–11,000/cmm), platelet count of 344,000 cmm (normal: 150,000–450,000/cmm), serum creatinine level of 2.3 mg/dl (normal: 0.9–1.2 mg/dl), aspartate aminotransferase level of 27 units/L (normal: 15–46 units/L), alanine aminotransferase level of 14 units/L (normal: 13–69 units/L), alkaline phosphatase level of 117 units/L (normal: 42–140 units/L), and international normalized ratio of 1.2. The patient was admitted for stabilization and further evaluation of gastrointestinal bleeding.

The patient was intravenously given 80 mg pantoprazole, followed by 8 mg/hour continuous infusion. A total of 2 units of packed red blood cells were transfused. Aspirin and ticagrelor were initially held. On hospitalization day 1, the patient was hemodynamically stable and his Hb level increased to 9.9 g/dl after transfusion. The gastroenterology service proceeded with esophagogastroduodenoscopy (EGD). The EGD (Figure 1) showed a 2.5 to 3.0 cm polypoid mass in the gastric fundus. The polyp was completely removed with a polypectomy snare and cautery. Bleeding occurred after polyp removal, and hemostasis was achieved via local epinephrine injection and the application of two Cook hemostasis clips.

The histological examination (Figure 2) demonstrated a submucosal tumor comprising nests and fascicles of cells with abundant clear cytoplasm and moderately pleomorphic nuclei with prominent eosinophilic nucleoli. A background vascular network and acute and chronic inflammation were observed. Immunohistochemical staining (Figure 3) was positive for pan-keratin PAX2 and PAX8. Both the morphology and immune phenotypes were most consistent with metastatic clear cell RCC, comparable with the right lung lesion resected in 2014.

The patient was observed overnight in the intensive care unit. His Hb levels were unchanged, and he remained hemodynamically stable. Aspirin and ticagrelor treatments were resumed. The oncology service decided to follow him as an outpatient. Chemotherapy was not initiated with his recent gastrointestinal blood loss and myocardial infarction. He is following up now with the oncology and cardiology clinics and has been doing well about 1 year after his presentation.

3. Discussion

RCC is the most common cancer originating from the kidney. This cancer is responsible for 80 to 85% of all primary renal neoplasms and accounts for 3% of all adult malignancies [1]. RCC has an abundant blood supply and can metastasize to any organ [2, 3]. The most common sites of metastasis include the lungs, bones, liver, and brain [2, 3]. However, RCCs can also metastasize to unusual sites, including the pancreas, thyroid gland, adrenal gland, skeletal muscle, and skin [4]. Studies have reported that a metastasis is detected in approximately 30% of RCC patients on initial presentation [3].

Gastric metastases from RCC are exceedingly rare [5, 6]. Pollheimer et al. [5] reported 5 patients who developed gastric metastases from an Austrian database of 2,082 RCC patients. In one instance, an isolated gastric metastasis from RCC was reported 20 years after radical nephrectomy [7]. Table 1 summarizes the reported cases of gastric metastases from RCC in English literature.

Most RCC gastric metastases are located in the gastric body and fundus. Single tumors predominate over multiple tumors [6]. Histologically, these metastases are situated in the submucosa [3, 12]. Clear cell histology is the predominant form of RCC. The presence of clear cell morphology in any unknown lesion should prompt the pathologist to consider
| Case and reference | Age (years), sex | Gastrointestinal symptoms | Location | Gross appearance | Histology | Treatment |
|-------------------|----------------|---------------------------|----------|-----------------|-----------|-----------|
| Sullivan et al. 1980 [17] | 69, male | Bleeding | Antrum | Mass, single | Not specified | Antrectomy |
| Boruchowicz et al. 1995 [18] | 48, male | Dysphagia | Fundus | Polypoid, single | Clear cell | Chemotherapy |
| Blake et al. 1995 [11] | 63, male | Bleeding | Not specified | Not specified | Not specified | Embolization |
| Odori et al. 1998 [19] | 58, male | Not specified | Not specified | Ulcerated, single | Clear cell | Total gastrectomy with regional lymph node dissection |
| Picchio et al. 2000 [12] | 64, female | Bleeding | Body | Polyp, single | Clear cell | Subtotal gastrectomy |
| Mascarenhas et al. 2001 [20] | 66, male | Bleeding | Body | Ulcerated, single | Clear cell | Partial gastrectomy |
| Kobayashi et al. 2004 [21] | 78, male | Anemia | Lower one-third of stomach | Mass, single | Not specified | Gastrectomy |
| Kok Wee et al. 2004 [7] | 60, male | Bleeding | Body | 2 lesions, protruding and ulcerated | Clear cell | Endoscopic therapy |
| Lamb et al. 2005 [13] | 69, male | Bleeding | Body | Mass, single | Clear cell | Embolization, octreotide |
| Riviello et al. 2006 [22] | 68, male | Bleeding | Fundus | Mass, single | Clear cell | Total gastrectomy, chemotherapy |
| Pezzoli et al. 2007 [15] | 78, male | Anemia | Body | Polyps, multiple | Clear cell | Endoscopic mucosal resection |
| Saidi and Remine 2007 [23] | Not specified | Bleeding | Body | Polyp, single | Clear cell | Wedge resection |
| Pollheimer et al. 2008 [5] | 69, male | Epigastric pain, Nausea, vomiting | Body | Mass, single | Clear cell | Tamoxifen |
| Pollheimer et al. 2008 [5] | 77, male | No symptoms | Antrum | Ulcerated, single | Clear cell | Endoscopic therapy, interferon |
| Pollheimer et al. 2008 [5] | 83, female | Bleeding | Antrum | Mass, multiple | Clear cell | Endoscopic therapy, sunitinib |
| Pollheimer et al. 2008 [5] | 65, female | Bleeding | Not specified | Multiple | Clear cell | Endoscopic therapy, sunitinib |
| Pollheimer et al. 2008 [5] | 69, male | Anemia, epigastric pain | Body | Multiple | Clear cell | Endoscopic therapy, sunitinib |
| Kibria et al. 2009 [24] | 53, male | Bleeding | Fundus | Polypoid, single | Clear cell | None |
| Yamamoto et al. 2009 [8] | 74, male | Bleeding | Body | Polypoid, single | Not specified | Wedge resection |
| Tiwari et al. 2010 [25] | 58, female | Bleeding | Antrum | Polypoid, single | Clear cell | Subtotal gastrectomy |
| García-Campelo et al. 2010 [26] | 75, male | No symptoms | Fundus and body | Polypoid, multiple | Not specified | Sunitinib |
| Sugasawa et al. 2010 [27] | 69, male | Anemia | Fundus | Ulcerated, single | Clear cell | Wedge resection |
| Eslick and Kalantar 2011 [28] | 65, male | Bleeding | Lower stomach | Polypoid, single | Clear cell | Polypectomy |
| Kim et al. 2012 [29] | 79, male | Abdominal pain | Body | Erosive, single | Clear cell | Partial gastrectomy |
| Xu et al. 2012 [30] | 60, male | Anemia | Body | Polyp, multiple | Clear cell | Endoscopic mucosal resection |
| Siriwardana et al. 2012 [31] | 71, male | Anemia | Not specified | Polypoid, single | Clear cell | Endoscopic mucosal resection |
the possibility of metastatic RCC, even in the absence of a prior diagnosis [30]. Endoscopically, the metastasis typically appears as a polypoid submucosal-like tumor with a central depression.

In general, the outcome with metastatic RCC is poor with 5-year survival rates of 5–30% [10]. Patients with a single metastasis fare better than those with multiple metastases.

Immunohistochemistry, particularly for vimentin and PAX-2, is a useful adjunct in the diagnosis of RCC [8, 9]. Vimentin is an intermediate filament protein expressed in normal renal tissues [8], and PAX-2 is a transcription factor required for the development and proliferation of renal tubules [9]. Both proteins are expressed in 85% of metastatic clear cell RCCs [8, 9].

Consent
Informed consent was obtained from the patient to publish the details of this case report.

Disclosure
This manuscript is a detailed description of a previous abstract which was presented at the annual meeting of the American College of Gastroenterology (ACG) 2016 in Las Vegas and it was published as an abstract in a special supplement of the American Journal of Gastroenterology.

Conflicts of Interest
The authors declare that they have no conflicts of interest.

Authors’ Contributions
Mouhanna Abu Ghanimeh, Ayman Qasrawi, and Omar Abughaneimwe wrote and revised the manuscript. Sakher Albadarin edited the manuscript. John H. Helzberg performed the EGD, provided images, and reviewed and edited the final manuscript.

References
[1] R. L. Siegel, K. D. Miller, and A. Jemal, "Cancer statistics, 2016," CA: A Cancer Journal for Clinicians, vol. 66, no. 1, pp. 7–30, 2016.
[2] J. D. Maldazys and J. B. deKernion, "Prognostic factors in metastatic renal carcinoma," Journal of Urology, vol. 136, no. 2, pp. 376–379, 1986.
[3] Y. Satomi, Y. Senga, M. Nakahashi et al., "A clinical and statistical study of 333 cases of renal cell carcinoma. III. Operations, operative findings and results," Nihon Hinyokika Gakkai Zasshi, vol. 78, no. 8, pp. 1394–1402, 1987.
[4] V. T. DeVita, T. S. Lawrence, and S. A. Rosenberg, Cancer: Principles and Practice of Oncology, Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 8th edition, 2008.
[5] M. J. Pollheimer, T. A. Hinterleitner, V. S. Pollheimer, A. Schlemmer, and C. Langner, "Renal cell carcinoma metastatic to the stomach: Single-centre experience and literature review," BJU International, vol. 102, no. 3, pp. 315–319, 2008.
[6] H. Rita, A. Isabel, C. Iolanda et al., “Treatment of gastric metastases from renal cell carcinoma with endoscopic therapy,” Clinical Journal of Gastroenterology, vol. 7, no. 2, pp. 148–154, 2014.
[7] L. Kok Wee, R.-Y. Shyu, L.-F. Sheu, T.-Y. Hsieh, J.-C. Yan, and P.-J. Chen, "Metastatic renal cell cancer," Gastrointestinal Endoscopy, vol. 60, no. 2, p. 265, 2004.
[39] J. Forman, J. Marshall, Y. A. Tseng et al., "Image of the month: gastric metastasis of renal clear cell carcinoma," *The American Journal of Gastroenterology*, vol. 110, article 15, no. 1, 2015.

[40] M. Kongnyuy, S. Lawindy, D. Martinez et al., "A rare case of the simultaneous, multifocal, metastatic renal cell carcinoma to the ipsilateral left testes, bladder, and stomach," *Case Reports in Urology*, vol. 2016, Article ID 1829025, 3 pages, 2016.